Gonorrhea Market Size to Reach USD 1.46 Billion by 2035, Impelled by Growing Burden of Sexually Transmitted Infections

February 27, 2025 | Healthcare

VIEW FULL TABLE OF CONTENTS

Gonorrhea Market Outlook 2025-2035:

The 7 major gonorrhea market reached a value of USD 1.13 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 1.46 Billion by 2035, exhibiting a growth rate (CAGR) of 2.39% during 2025-2035. The gonorrhea industry is actively expanding principally because of the rapid rise in occurrence of antibiotic-resistant strains and better awareness of sexually transmitted infections (STIs). Both healthcare and governmental bodies are currently focusing on early diagnosis and treatment, further fueling the market growth. Moreover, numerous pharmaceutical firms are emphasizing on the development of new vaccines as well as antibiotics to mitigate drug resistance issues. Innovations in point-of-care testing are improving early detection rates. Additionally, expanding healthcare infrastructure and better access to treatment in developing regions are further driving market growth.

Gonorrhea Market Outlook

To get more information on this market, Request Sample

Growing Burden of Sexually Transmitted Infections: Driving the Gonorrhea

The magnifying complications of sexually transmitted infections (STIs) is increasing, with gonorrhea becoming a significant public health concern. Increased urbanization, changing sexual behaviors, and limited consciousness impact its rising prevalence. The widespread use of dating apps and high-risk sexual activities further drive transmission. Alarmingly, the rise of antimicrobial resistance (AMR) in Neisseria gonorrhoeae strains complicates treatment, leading to persistent infections and higher healthcare costs. Inadequate access to screening and stigma surrounding STIs delay early diagnosis and intervention. Additionally, increased travel facilitates cross-border transmission, worsening the spread. Public health initiatives and awareness campaigns remain crucial to reducing infection rates. Expanding diagnostic capabilities, investing in novel antibiotics, and promoting safe sex practices are essential to controlling gonorrhea’s impact. Strengthening surveillance systems to monitor resistance patterns and enhance outbreak response is vital. Collaborative efforts between healthcare providers, policymakers, and researchers can drive innovative treatment strategies. Encouraging routine STI screening and integrating sexual health education into public programs will be key to mitigating gonorrhea’s public health burden.

Development of Novel Therapies and Pharmacological Treatments: Contributing to Market Expansion

The development of novel therapies and pharmacological treatments is significantly contributing to the expansion of the gonorrhea treatment market. Pharmaceutical companies and research institutions are actively exploring new drug candidates, including novel antibiotics, combination therapies, and bacteriophage-based treatments. The introduction of next-generation cephalosporins and potential non-antibiotic therapies, such as antimicrobial peptides and immunotherapies, is expected to enhance treatment efficacy. Regulatory approvals of new drugs, along with government and global health initiatives, are accelerating drug development pipelines. The growing adoption of precision medicine and genomic approaches for targeted therapy is further transforming the treatment landscape. Additionally, strategic collaborations between biotech firms and healthcare organizations are fostering innovation. Increased public awareness and improved diagnostic techniques are also driving early detection and treatment adoption. Overall, the emergence of novel pharmacological interventions is playing a crucial role in addressing drug resistance and expanding the gonorrhea treatment market.

Marketed Therapies in Gonorrhea Market

Monodox (Doxycycline Hyclate): Aqua Pharmaceuticals

Monodox (Doxycycline Hyclate), developed by Aqua Pharmaceuticals, is a tetracycline antibiotic approved as part of combination therapy for gonorrhea. It helps inhibit bacterial growth and is often prescribed alongside ceftriaxone to improve treatment efficacy against the infection.

Cipro (Ciprofloxacin): Bayer

Cipro (Ciprofloxacin), developed by Bayer, is a fluoroquinolone antibiotic approved for the treatment of gonorrhea. It functions by prohibiting the functioning of both topoisomerase IV and bacterial DNA gyrase enzymes that are requisite for bacterial DNA replication and repair, resulting in cell death.

Emerging Therapies in Gonorrhea Market

Gepotidacin: GlaxoSmithKline

Gepotidacin, developed by GlaxoSmithKline, is a first-in-class, novel triazaacenaphthylene antibiotic that limits or terminates bacterial DNA replication through a unique mechanism targeting DNA gyrase and topoisomerase IV. It is being investigated for the treatment of uncomplicated gonorrhea, including cases resistant to current antibiotics.

Zoliflodacin: Innoviva Specialty Therapeutics (Formerly Entasis Therapeutics)

Zoliflodacin, developed by Innoviva Specialty Therapeutics (formerly Entasis Therapeutics), is a first-in-class oral antibiotic designed to treat uncomplicated gonorrhea. It works by inhibiting bacterial DNA synthesis through a novel mechanism targeting DNA gyrase, making it effective against drug-resistant Neisseria gonorrhoeae strains. Zoliflodacin offers a promising single-dose oral alternative to current injectable treatments, addressing the growing concern of antibiotic resistance.

Drug Name	Company Name	MOA	ROA
Gepotidacin	GlaxoSmithKline	DNA gyrase inhibitors	Oral
Zoliflodacin	Innoviva Specialty Therapeutics (Formerly Entasis Therapeutics)	DNA gyrase inhibitors	Oral

Detailed list of emerging therapies in Gonorrhea is provided in the final report…

Leading Companies in the Gonorrhea Market:

The market research report by IMARC encompasses a comprehensive analysis of the competitive landscape in the market. Across the global Gonorrhea market, several leading companies are at the forefront of developing integrated platforms to enhance the management of Gonorrhea. Some of the major players include Roche, Bayer, GlaxoSmithKline, and others. These companies are driving innovation in the Gonorrhea market through continuous research, diagnostic tools, and expanding their product offerings to meet the growing demand for Gonorrhea.

Key Players in Gonorrhea Market:

The key players in the Gonorrhea market who are in different phases of developing different therapies are Roche, Aqua Pharmaceuticals, Melinta Therapeutics, Innoviva Specialty Therapeutics, Bayer, GlaxoSmithKline, Evofem Biosciences, and others.

Key Players in Gonorrhea Market

Regional Analysis:

The major markets for Gonorrhea include the United States, Germany, France, the United Kingdom, Italy, Spain, and Japan. According to projections by IMARC, the United States has the largest patient pool for Gonorrhea while also representing the biggest market for its treatment. Recent advancements in gonorrhea research focus on tackling antibiotic resistance, a growing global concern. Scientists are developing novel treatment options, including zoliflodacin, a first-in-class oral antibiotic currently in late-stage clinical trials. Additionally, research into bacteriophage therapy and CRISPR-based gene editing shows promise for targeting drug-resistant Neisseria gonorrhoeae. Vaccination efforts have also gained traction, with candidates in early-stage trials exploring immune responses to prevent infection. Improved diagnostic techniques, such as rapid molecular testing, are enhancing early detection and treatment strategies. These innovations aim to curb the spread of resistant strains and improve long-term disease management.

Recent Developments in Gonorrhea Market:

In September 2024, Innoviva Specialty Therapeutics announced that new findings on its investigational drug zoliflodacin, a first-in-class oral, single-dose antibiotic for treating uncomplicated gonorrhea, will be presented as oral sessions at the 2024 Sexually Transmitted Infections Prevention Conference, taking place from September 16-19, 2024, in Atlanta, GA.
In April 2024, GSK reported positive findings from the crucial gepotidacin’s EAGLE-1 Phase III trial , a promising first-in-class oral antibiotic with an unprecedented mechanism of action for treating rudimentary urogenital gonorrhea (GC) in adults as well as adolescents. These results are set to be showcased on April 30, 2024, at the ESCMID Global Conference in Barcelona, Spain.
In February 2024, GSK presented positive headline results from the pivotal EAGLE-1 Phase III trial evaluating gepotidacin, a pioneering first-in-class oral antibiotic with a unique mechanism of action for treating basic urogenital gonorrhea in both adults and adolescents. The trial achieved its core efficiency endpoint, demonstrating that gepotidacin (administered orally in two doses of 3,000 mg) was non-inferior to the combination treatment of intramuscular (IM) ceftriaxone (500 mg) plus oral azithromycin (1,000 mg), a widely used regimen for gonorrhea. This conclusion is based on the main endpoint of microbiological response (failure or success) assessed at the Test-of-Cure (ToC) visit, conducted 3 to 7 days post-treatment.

Key information covered in the report

Base Year: 2024
Historical Period: 2019-2024
Market Forecast: 2025-2035

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Gonorrhea market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Gonorrhea market
Reimbursement scenario in the market
In-market and pipeline drugs

Competitive Landscape:

This report offers a comprehensive analysis of current Gonorrhea marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. Across the six major continents and 100+ countries, we work alongside our business partners as one team with a common ambition to achieve unparallelled results, gain a competitive edge, and transform industries. IMARC Group excels in understanding its clients’ business priorities and delivering tailored solutions that drive meaningful outcomes. Our client base spans over 3,000 organizations in the private, public, and social sectors, ranging from high-growth startups to Fortune 500 companies.

Contact US

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Phone Number: - +1 631 791 1145, +91-120-433-0800

Need more help?

Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.

Gonorrhea Market Size to Reach USD 1.46 Billion by 2035, Impelled by Growing Burden of Sexually Transmitted Infections

Purchase Options Discount
Offer

Inquire Before Buying

Benefits of Customization

Personalize this research
Triangulate with your data
Get data as per your format and definition
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization

Speak to an Analyst

Request Brochure

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

IMARC did an outstanding job in preparing our study. They were punctual and precise, delivering all the data we required in a clear and well-organized format. Their attention to detail and ability to meet deadlines was impressive, making them a reliable partner for our project.

I wanted to express my sincere appreciation for your efforts in handling this matter. Your dedication and commitment have truly been commendable. It is evident that you have put in a tremendous amount of hard work and expertise into resolving the issues at hand. I would also like to take this opportunity to inform you that we are greatly interested

Overall, the deliverable was well organized and my experience with the project team was good. In particular, I appreciated how they responded when I requested additional information and the Japanese version.

The IMARC team were extremely professional and very cooperative. The team were also extremely flexible in making changes and modifications wherever required. The entire experience right from project kick-off to after sales support was fruitful and smooth.

I’d like to express my gratitude for the work you accomplished with the industry report. The way you responded to the requirements and delivered under tight timelines shows your expertise, exceptional work ethic and commitment to your customer’s success. The entire team and company are incredibly thankful for your dedication. Once again, thank you

The market reports from IMARC have been instrumental in guiding our business strategies. We found the reports comprehensive and data-driven, which helped us make informed decisions. The detailed insights and actionable data have consistently provided us with a competitive edge in a rapidly changing alcohol market.

One of the best things about IMARC is their flexibility and predisposition to tailor the reports and adapt to our needs. They are not just great in their researching and consulting solutions, but their service is unparallelled. We’ve worked with them a couple of times and we will keep working with them in future projects.

We recently commissioned multiple market research reports from IMARC, and the insights we received were invaluable. The depth of analysis, accuracy of data, and actionable recommendations have greatly enhanced our strategic decision-making.

The market estimates provided by your team were pretty much in line with what we were theorizing internally. Really appreciate the work on this.

The sale account manager and the service was excellent. The data and market trends gathered from the report was insightful and really assisted while planning future product and growth strategies.

The report is excellent and has good amount of data and our team is extremely happy with the information provided.

Thank you very much for your cooperation and post purchase support. We were really happy with the final deliverable, and the takeaways from the report.